ORAMED PHARMACEUTICALS INC (ORMP)
Health Care · Biopharmaceutical / oral protein delivery · NASDAQ
Oramed is a clinical-stage pharmaceutical company developing oral insulin delivery technology while actively investing in healthcare companies to diversify capital allocation.
What ORAMED PHARMACEUTICALS INC does
Oramed Pharmaceuticals is a research and development-focused pharmaceutical company engaged in developing innovative oral delivery solutions for therapeutic proteins, particularly insulin. The company has developed a proprietary dosage form designed to withstand the gastrointestinal tract and safely deliver active proteins without chemical modification. In addition to its core pharmaceutical operations, Oramed strategically allocates capital to investments in healthcare and life sciences companies that complement its long-term business objectives and technology focus.
Themes: ["Oral protein delivery / insulin"]
Fundamentals
- Price$4.18 as of 2026-07-09 close
- Market cap$176M as of 2026-07-10
- 1-year return+92.6% as of 2026-07-09 close
- P/E1.60 as of 2026-07-10
- Net margin-838.4% as of 2026-07-10
- ROE+55.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-30.9% as of 2026-07-10
- Revenue CAGR (3y)-7.3% SEC XBRL
- Beta1.15 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Clinical development risk: the company's planned 60-patient US clinical trial to validate oral insulin formulation may not succeed or may require additional trials before regulatory submission"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.